JP2013515748A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515748A5
JP2013515748A5 JP2012546257A JP2012546257A JP2013515748A5 JP 2013515748 A5 JP2013515748 A5 JP 2013515748A5 JP 2012546257 A JP2012546257 A JP 2012546257A JP 2012546257 A JP2012546257 A JP 2012546257A JP 2013515748 A5 JP2013515748 A5 JP 2013515748A5
Authority
JP
Japan
Prior art keywords
virus
influenza
particle
envelope
influenza antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546257A
Other languages
English (en)
Japanese (ja)
Other versions
JP6073031B2 (ja
JP2013515748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/062217 external-priority patent/WO2011090712A2/en
Publication of JP2013515748A publication Critical patent/JP2013515748A/ja
Publication of JP2013515748A5 publication Critical patent/JP2013515748A5/ja
Application granted granted Critical
Publication of JP6073031B2 publication Critical patent/JP6073031B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546257A 2009-12-28 2010-12-28 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法 Expired - Fee Related JP6073031B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29043809P 2009-12-28 2009-12-28
US61/290,438 2009-12-28
PCT/US2010/062217 WO2011090712A2 (en) 2009-12-28 2010-12-28 Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016193457A Division JP2016222722A (ja) 2009-12-28 2016-09-30 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法

Publications (3)

Publication Number Publication Date
JP2013515748A JP2013515748A (ja) 2013-05-09
JP2013515748A5 true JP2013515748A5 (https=) 2014-01-09
JP6073031B2 JP6073031B2 (ja) 2017-02-01

Family

ID=44307476

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012546257A Expired - Fee Related JP6073031B2 (ja) 2009-12-28 2010-12-28 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
JP2016193457A Pending JP2016222722A (ja) 2009-12-28 2016-09-30 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016193457A Pending JP2016222722A (ja) 2009-12-28 2016-09-30 インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法

Country Status (4)

Country Link
US (2) US20130028933A1 (https=)
EP (1) EP2519539A4 (https=)
JP (2) JP6073031B2 (https=)
WO (1) WO2011090712A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316356B (zh) * 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
JP6426695B2 (ja) * 2013-03-14 2018-11-21 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 弱毒生アルファウイルス製剤のための組成物および方法
US20160317646A1 (en) * 2013-12-19 2016-11-03 Crucell Holland B.V. Formulations for virosomes
US10100093B2 (en) * 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
JP2018510160A (ja) * 2015-03-20 2018-04-12 ブルーバード バイオ， インコーポレイテッド ベクター製剤
SI3377618T1 (sl) 2015-11-19 2021-02-26 Novartis Ag Pufri za stabilizacijo lentivirusnih pripravkov
EP3498263B1 (en) * 2016-08-10 2023-11-29 Celltrion Inc. Stable liquid pharmaceutical preparation for anti-influenza virus antibody
JPWO2019021957A1 (ja) * 2017-07-25 2020-07-09 第一三共株式会社 点鼻用乾燥粉末医薬組成物
US20210008195A1 (en) * 2017-12-20 2021-01-14 Zoetis Services Llc Vaccines against hendra and nipah virus infection
US11523988B2 (en) * 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
ES2156181T3 (es) * 1995-11-25 2001-06-16 Study Ct Of Allergy Projects S Utilizacion de un disacarido como estabilizante de mezclas liquidas de proteinas y mezclas liquidas de proteinas que contienen un disacarido.
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
JP5008244B2 (ja) * 2000-06-23 2012-08-22 ワイス・ホールディングズ・コーポレイション 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
KR20050088175A (ko) * 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2562932A1 (en) * 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine
BRPI0606867A2 (pt) * 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
WO2007044610A2 (en) * 2005-10-07 2007-04-19 Avatar Vaccines, Inc. Virus-like particles and methods of use
EP1878791A1 (en) * 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
ZA200900379B (en) * 2006-07-21 2010-08-25 Univ California Human endogenous retrovirus polypeptide compositions and methods of use thereof
US9439959B2 (en) * 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
US20080233150A1 (en) * 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
CA2716340A1 (en) * 2008-02-21 2009-08-27 Biological Mimetics, Inc. Immunogenic influenza composition
JP2011514337A (ja) * 2008-02-25 2011-05-06 ノババックス，インコーポレイテッド 糖ガラス化ウィルス様粒子（ｖｌｐ）
KR20120131725A (ko) * 2011-05-26 2012-12-05 건국대학교 산학협력단 고병원성 조류인플루엔자 ａ ｈ５ｎ１ 바이러스 유사입자 및 이를 이용한 가금용 백신
EP2814837B1 (en) * 2012-02-13 2017-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Similar Documents

Publication Publication Date Title
JP2013515748A5 (https=)
Wang et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
US20230390381A1 (en) Immunogenic combinations
US12440550B2 (en) Immunogenic compositions and uses thereof
Rossey et al. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
JP2014503206A5 (https=)
Simnani et al. COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review
JP2023081859A (ja) コロナウイルスワクチン
JP2020528911A5 (https=)
CN107106673A (zh) 用于增强免疫应答的方法和组合物
Quan et al. Progress in the development of virus-like particle vaccines against respiratory viruses
CN105473603B (zh) 用于登革病毒疫苗的方法与组合物
Wang et al. Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines
TW202430206A (zh) 組合疫苗
CN116650633A (zh) 冠状病毒疫苗
Wong et al. Influenza vaccination: options and issues
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
Gattinger et al. Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O)
JP2024523329A (ja) ウイルス性疾患用の温度制御可能な自己複製ｒｎａワクチン
Lundstrom COVID-19 vaccines: where did we stand at the end of 2023? Viruses. 2024; 16: 203
Lupascu et al. Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review
Lundstrom COVID-19 Vaccines: Where Do We Stand at the End of 2023?
HK40060960A (en) Immunogenic combinations
Ashraf et al. COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines 2021, 9, 171
WO2026006624A1 (en) Stabilized and atomic layer deposition (ald)-coated lipid assembly-free polynucleotide-containing microparticles and uses thereof